T1	Outcomes 60 79	efficacy and safety
T2	Outcomes 293 312	safety and efficacy
T3	Outcomes 484 518	serotonin (5-HT) receptor activity
T4	Outcomes 541 563	serotonin transporter.
T5	Outcomes 780 856	the primary efficacy end point being change from baseline at week 8 in MADRS
T6	Outcomes 894 903	measures.
T7	Outcomes 904 918	Adverse events
T8	Outcomes 944 1139	study, suicidal ideation and behavior were assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), and sexual dysfunction was assessed using the Arizona Sexual Experience (ASEX) scale
T9	Outcomes 1313 1343	the primary efficacy end point
T10	Outcomes 1421 1424	mg.
T11	Outcomes 1425 1513	Nausea, headache, dry mouth, constipation, diarrhea, vomiting, dizziness, and flatulence
T12	Outcomes 1590 1611	due to adverse events
T13	Outcomes 1881 1955	the C-SSRS, laboratory values, electrocardiogram, or vital sign parameters
